世界の悪性神経膠腫治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Malignant Glioma Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3540 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、悪性神経膠腫治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アルキル化剤、VEGF / VEGFR阻害剤、抗血管新生薬）、用途別市場規模（病院、がん研究機関、診断センター、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・悪性神経膠腫治療薬の市場動向 ・企業の競争状況、市場シェア ・悪性神経膠腫治療薬の種類別市場規模（アルキル化剤、VEGF / VEGFR阻害剤、抗血管新生薬） ・悪性神経膠腫治療薬の用途別市場規模（病院、がん研究機関、診断センター、その他） ・悪性神経膠腫治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・悪性神経膠腫治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・悪性神経膠腫治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・悪性神経膠腫治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・悪性神経膠腫治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Eli Lilly、AbbVie、Bristol-Myers Squibb、Genentech、Sun Pharmaceutical、BioMimetix、Cipla、Sigma-Aldrich、Panacea Biotec、Zydus Cadila） ・結論

Malignant glioma’s are one of the common sub-type of primary brain tumors which are highly invasive, aggressive and neurologically destructive tumors among the deadliest human cancers.
In the Malignant Glioma Market the largest market share is gained by the U.S. where there are large incidence and prevalence cases, followed by Europe where the major pharmaceuticals have their blockbuster drugs and include the major funding associations.

Market Analysis and Insights: Global Malignant Glioma Drugs Market
The global Malignant Glioma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Malignant Glioma Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Malignant Glioma Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Malignant Glioma Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Malignant Glioma Drugs market.

Global Malignant Glioma Drugs Scope and Market Size
Malignant Glioma Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Glioma Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Alkylating Agents
VEGF/VEGFR Inhibitors
Anti Angiogenic Drugs

Segment by Application
Hospitals
Cancer Research Organizations
Diagnostic Centers
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
Eli Lilly
AbbVie
Bristol-Myers Squibb
Genentech
Sun Pharmaceutical
BioMimetix
Cipla
Sigma-Aldrich

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Glioma Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Alkylating Agents
1.2.3 VEGF/VEGFR Inhibitors
1.2.4 Anti Angiogenic Drugs
1.3 Market by Application
1.3.1 Global Malignant Glioma Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Cancer Research Organizations
1.3.4 Diagnostic Centers
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Malignant Glioma Drugs Market Perspective (2016-2027)
2.2 Malignant Glioma Drugs Growth Trends by Regions
2.2.1 Malignant Glioma Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Malignant Glioma Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Malignant Glioma Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Malignant Glioma Drugs Industry Dynamic
2.3.1 Malignant Glioma Drugs Market Trends
2.3.2 Malignant Glioma Drugs Market Drivers
2.3.3 Malignant Glioma Drugs Market Challenges
2.3.4 Malignant Glioma Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Malignant Glioma Drugs Players by Revenue
3.1.1 Global Top Malignant Glioma Drugs Players by Revenue (2016-2021)
3.1.2 Global Malignant Glioma Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Malignant Glioma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Malignant Glioma Drugs Revenue
3.4 Global Malignant Glioma Drugs Market Concentration Ratio
3.4.1 Global Malignant Glioma Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Glioma Drugs Revenue in 2020
3.5 Malignant Glioma Drugs Key Players Head office and Area Served
3.6 Key Players Malignant Glioma Drugs Product Solution and Service
3.7 Date of Enter into Malignant Glioma Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Malignant Glioma Drugs Breakdown Data by Type
4.1 Global Malignant Glioma Drugs Historic Market Size by Type (2016-2021)
4.2 Global Malignant Glioma Drugs Forecasted Market Size by Type (2022-2027)

5 Malignant Glioma Drugs Breakdown Data by Application
5.1 Global Malignant Glioma Drugs Historic Market Size by Application (2016-2021)
5.2 Global Malignant Glioma Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Malignant Glioma Drugs Market Size (2016-2027)
6.2 North America Malignant Glioma Drugs Market Size by Type
6.2.1 North America Malignant Glioma Drugs Market Size by Type (2016-2021)
6.2.2 North America Malignant Glioma Drugs Market Size by Type (2022-2027)
6.2.3 North America Malignant Glioma Drugs Market Size by Type (2016-2027)
6.3 North America Malignant Glioma Drugs Market Size by Application
6.3.1 North America Malignant Glioma Drugs Market Size by Application (2016-2021)
6.3.2 North America Malignant Glioma Drugs Market Size by Application (2022-2027)
6.3.3 North America Malignant Glioma Drugs Market Size by Application (2016-2027)
6.4 North America Malignant Glioma Drugs Market Size by Country
6.4.1 North America Malignant Glioma Drugs Market Size by Country (2016-2021)
6.4.2 North America Malignant Glioma Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Malignant Glioma Drugs Market Size (2016-2027)
7.2 Europe Malignant Glioma Drugs Market Size by Type
7.2.1 Europe Malignant Glioma Drugs Market Size by Type (2016-2021)
7.2.2 Europe Malignant Glioma Drugs Market Size by Type (2022-2027)
7.2.3 Europe Malignant Glioma Drugs Market Size by Type (2016-2027)
7.3 Europe Malignant Glioma Drugs Market Size by Application
7.3.1 Europe Malignant Glioma Drugs Market Size by Application (2016-2021)
7.3.2 Europe Malignant Glioma Drugs Market Size by Application (2022-2027)
7.3.3 Europe Malignant Glioma Drugs Market Size by Application (2016-2027)
7.4 Europe Malignant Glioma Drugs Market Size by Country
7.4.1 Europe Malignant Glioma Drugs Market Size by Country (2016-2021)
7.4.2 Europe Malignant Glioma Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Malignant Glioma Drugs Market Size (2016-2027)
8.2 Asia-Pacific Malignant Glioma Drugs Market Size by Type
8.2.1 Asia-Pacific Malignant Glioma Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Malignant Glioma Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Malignant Glioma Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Malignant Glioma Drugs Market Size by Application
8.3.1 Asia-Pacific Malignant Glioma Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Malignant Glioma Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Malignant Glioma Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Malignant Glioma Drugs Market Size by Region
8.4.1 Asia-Pacific Malignant Glioma Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Malignant Glioma Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Malignant Glioma Drugs Market Size (2016-2027)
9.2 Latin America Malignant Glioma Drugs Market Size by Type
9.2.1 Latin America Malignant Glioma Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Malignant Glioma Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Malignant Glioma Drugs Market Size by Type (2016-2027)
9.3 Latin America Malignant Glioma Drugs Market Size by Application
9.3.1 Latin America Malignant Glioma Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Malignant Glioma Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Malignant Glioma Drugs Market Size by Application (2016-2027)
9.4 Latin America Malignant Glioma Drugs Market Size by Country
9.4.1 Latin America Malignant Glioma Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Malignant Glioma Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Malignant Glioma Drugs Market Size (2016-2027)
10.2 Middle East & Africa Malignant Glioma Drugs Market Size by Type
10.2.1 Middle East & Africa Malignant Glioma Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Malignant Glioma Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Malignant Glioma Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Malignant Glioma Drugs Market Size by Application
10.3.1 Middle East & Africa Malignant Glioma Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Malignant Glioma Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Malignant Glioma Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Malignant Glioma Drugs Market Size by Country
10.4.1 Middle East & Africa Malignant Glioma Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Malignant Glioma Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Malignant Glioma Drugs Introduction
11.1.4 Merck Revenue in Malignant Glioma Drugs Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Malignant Glioma Drugs Introduction
11.2.4 Eli Lilly Revenue in Malignant Glioma Drugs Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Malignant Glioma Drugs Introduction
11.3.4 AbbVie Revenue in Malignant Glioma Drugs Business (2016-2021)
11.3.5 AbbVie Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Glioma Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Glioma Drugs Business (2016-2021)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Genentech
11.5.1 Genentech Company Details
11.5.2 Genentech Business Overview
11.5.3 Genentech Malignant Glioma Drugs Introduction
11.5.4 Genentech Revenue in Malignant Glioma Drugs Business (2016-2021)
11.5.5 Genentech Recent Development
11.6 Sun Pharmaceutical
11.6.1 Sun Pharmaceutical Company Details
11.6.2 Sun Pharmaceutical Business Overview
11.6.3 Sun Pharmaceutical Malignant Glioma Drugs Introduction
11.6.4 Sun Pharmaceutical Revenue in Malignant Glioma Drugs Business (2016-2021)
11.6.5 Sun Pharmaceutical Recent Development
11.7 BioMimetix
11.7.1 BioMimetix Company Details
11.7.2 BioMimetix Business Overview
11.7.3 BioMimetix Malignant Glioma Drugs Introduction
11.7.4 BioMimetix Revenue in Malignant Glioma Drugs Business (2016-2021)
11.7.5 BioMimetix Recent Development
11.8 Cipla
11.8.1 Cipla Company Details
11.8.2 Cipla Business Overview
11.8.3 Cipla Malignant Glioma Drugs Introduction
11.8.4 Cipla Revenue in Malignant Glioma Drugs Business (2016-2021)
11.8.5 Cipla Recent Development
11.9 Sigma-Aldrich
11.9.1 Sigma-Aldrich Company Details
11.9.2 Sigma-Aldrich Business Overview
11.9.3 Sigma-Aldrich Malignant Glioma Drugs Introduction
11.9.4 Sigma-Aldrich Revenue in Malignant Glioma Drugs Business (2016-2021)
11.9.5 Sigma-Aldrich Recent Development
11.10 Panacea Biotec
11.10.1 Panacea Biotec Company Details
11.10.2 Panacea Biotec Business Overview
11.10.3 Panacea Biotec Malignant Glioma Drugs Introduction
11.10.4 Panacea Biotec Revenue in Malignant Glioma Drugs Business (2016-2021)
11.10.5 Panacea Biotec Recent Development
11.11 Zydus Cadila
11.11.1 Zydus Cadila Company Details
11.11.2 Zydus Cadila Business Overview
11.11.3 Zydus Cadila Malignant Glioma Drugs Introduction
11.11.4 Zydus Cadila Revenue in Malignant Glioma Drugs Business (2016-2021)
11.11.5 Zydus Cadila Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Malignant Glioma Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Alkylating Agents
Table 3. Key Players of VEGF/VEGFR Inhibitors
Table 4. Key Players of Anti Angiogenic Drugs
Table 5. Global Malignant Glioma Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Malignant Glioma Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Malignant Glioma Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Malignant Glioma Drugs Market Share by Regions (2016-2021)
Table 9. Global Malignant Glioma Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Malignant Glioma Drugs Market Share by Regions (2022-2027)
Table 11. Malignant Glioma Drugs Market Trends
Table 12. Malignant Glioma Drugs Market Drivers
Table 13. Malignant Glioma Drugs Market Challenges
Table 14. Malignant Glioma Drugs Market Restraints
Table 15. Global Malignant Glioma Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Malignant Glioma Drugs Market Share by Players (2016-2021)
Table 17. Global Top Malignant Glioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Drugs as of 2020)
Table 18. Ranking of Global Top Malignant Glioma Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Malignant Glioma Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Malignant Glioma Drugs Product Solution and Service
Table 22. Date of Enter into Malignant Glioma Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Malignant Glioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Malignant Glioma Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Malignant Glioma Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Malignant Glioma Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Malignant Glioma Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Malignant Glioma Drugs Revenue Market Share by Application (2016-2021)
Table 30. Global Malignant Glioma Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Malignant Glioma Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Malignant Glioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Malignant Glioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Malignant Glioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Malignant Glioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Malignant Glioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Malignant Glioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Malignant Glioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Malignant Glioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Malignant Glioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Malignant Glioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Malignant Glioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Malignant Glioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Malignant Glioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Malignant Glioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Malignant Glioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Malignant Glioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Malignant Glioma Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Malignant Glioma Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Malignant Glioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Malignant Glioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Malignant Glioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Malignant Glioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Malignant Glioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Malignant Glioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Malignant Glioma Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Malignant Glioma Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Malignant Glioma Drugs Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Malignant Glioma Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Malignant Glioma Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Malignant Glioma Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Merck Company Details
Table 63. Merck Business Overview
Table 64. Merck Malignant Glioma Drugs Product
Table 65. Merck Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 66. Merck Recent Development
Table 67. Eli Lilly Company Details
Table 68. Eli Lilly Business Overview
Table 69. Eli Lilly Malignant Glioma Drugs Product
Table 70. Eli Lilly Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 71. Eli Lilly Recent Development
Table 72. AbbVie Company Details
Table 73. AbbVie Business Overview
Table 74. AbbVie Malignant Glioma Drugs Product
Table 75. AbbVie Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 76. AbbVie Recent Development
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Malignant Glioma Drugs Product
Table 80. Bristol-Myers Squibb Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 81. Bristol-Myers Squibb Recent Development
Table 82. Genentech Company Details
Table 83. Genentech Business Overview
Table 84. Genentech Malignant Glioma Drugs Product
Table 85. Genentech Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 86. Genentech Recent Development
Table 87. Sun Pharmaceutical Company Details
Table 88. Sun Pharmaceutical Business Overview
Table 89. Sun Pharmaceutical Malignant Glioma Drugs Product
Table 90. Sun Pharmaceutical Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 91. Sun Pharmaceutical Recent Development
Table 92. BioMimetix Company Details
Table 93. BioMimetix Business Overview
Table 94. BioMimetix Malignant Glioma Drugs Product
Table 95. BioMimetix Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 96. BioMimetix Recent Development
Table 97. Cipla Company Details
Table 98. Cipla Business Overview
Table 99. Cipla Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 100. Cipla Recent Development
Table 101. Sigma-Aldrich Company Details
Table 102. Sigma-Aldrich Business Overview
Table 103. Sigma-Aldrich Malignant Glioma Drugs Product
Table 104. Sigma-Aldrich Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 105. Sigma-Aldrich Recent Development
Table 106. Panacea Biotec Company Details
Table 107. Panacea Biotec Business Overview
Table 108. Panacea Biotec Malignant Glioma Drugs Product
Table 109. Panacea Biotec Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 110. Panacea Biotec Recent Development
Table 111. Zydus Cadila Company Details
Table 112. Zydus Cadila Business Overview
Table 113. Zydus Cadila Malignant Glioma Drugs Product
Table 114. Zydus Cadila Revenue in Malignant Glioma Drugs Business (2016-2021) & (US$ Million)
Table 115. Zydus Cadila Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Malignant Glioma Drugs Market Share by Type: 2020 VS 2027
Figure 2. Alkylating Agents Features
Figure 3. VEGF/VEGFR Inhibitors Features
Figure 4. Anti Angiogenic Drugs Features
Figure 5. Global Malignant Glioma Drugs Market Share by Application: 2020 VS 2027
Figure 6. Hospitals Case Studies
Figure 7. Cancer Research Organizations Case Studies
Figure 8. Diagnostic Centers Case Studies
Figure 9. Other Case Studies
Figure 10. Malignant Glioma Drugs Report Years Considered
Figure 11. Global Malignant Glioma Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Malignant Glioma Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Malignant Glioma Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Malignant Glioma Drugs Market Share by Regions (2022-2027)
Figure 15. Global Malignant Glioma Drugs Market Share by Players in 2020
Figure 16. Global Top Malignant Glioma Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Malignant Glioma Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Malignant Glioma Drugs Revenue in 2020
Figure 18. Global Malignant Glioma Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Malignant Glioma Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Malignant Glioma Drugs Market Share by Type (2016-2027)
Figure 22. North America Malignant Glioma Drugs Market Share by Application (2016-2027)
Figure 23. North America Malignant Glioma Drugs Market Share by Country (2016-2027)
Figure 24. United States Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Malignant Glioma Drugs Market Share by Type (2016-2027)
Figure 28. Europe Malignant Glioma Drugs Market Share by Application (2016-2027)
Figure 29. Europe Malignant Glioma Drugs Market Share by Country (2016-2027)
Figure 30. Germany Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Malignant Glioma Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Malignant Glioma Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Malignant Glioma Drugs Market Share by Region (2016-2027)
Figure 40. China Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Malignant Glioma Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Malignant Glioma Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Malignant Glioma Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Malignant Glioma Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Malignant Glioma Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Malignant Glioma Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Malignant Glioma Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Merck Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 60. Eli Lilly Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 61. AbbVie Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 62. Bristol-Myers Squibb Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 63. Genentech Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 64. Sun Pharmaceutical Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 65. BioMimetix Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 66. Cipla Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 67. Sigma-Aldrich Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 68. Panacea Biotec Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 69. Zydus Cadila Revenue Growth Rate in Malignant Glioma Drugs Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---